

5. Pearce OM, Läubli H, Verhagen A, Secret P, Zhang J, Varki NM, Crocker PR, Bui JD, Varki A. Inverse hormesis of cancer growth mediated by narrow ranges of tumor-directed antibodies. *Proc Natl Acad Sci U S A* 2014; 111:5998-6003; PMID:24711415; <http://dx.doi.org/10.1073/pnas.1209067111>
6. Prehn RT. The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth. *Clin Dev Immunol* 2010; 2010: <http://dx.doi.org/10.1155/2010/851728>; PMID:20811480
7. Bui JD, Schreiber RD. Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? *Curr Opin Immunol* 2007; 19:203-8; PMID:17292599; <http://dx.doi.org/10.1016/j.coi.2007.02.001>
8. Sica A, Larghi P, Mancino A, Rubino L, Porta C, Totaro MG, Rimoldi M, Biswas SK, Allavena P, Mantovani A. Macrophage polarization in tumour progression. *Semin Cancer Biol* 2008; 18:349-55; PMID:18467122; <http://dx.doi.org/10.1016/j.semcancer.2008.03.004>
9. Calabrese EJ. Hormesis and medicine. *Br J Clin Pharmacol* 2008; 66:594-617; PMID:18662293
10. Hainsworth JD, Burris HA 3rd, Morrissey LH, Litchy S, Scullin DC Jr., Bearden JD 3rd, Richards P, Greco FA. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. *Blood* 2000; 95:3052-6; PMID:10807768